Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.42 |
| ▸ | CALCR | P30988 | 3/20 | 0.40 |
| ▸ | GRPR | P30550 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 6/20 | 0.36 |
| ▸ | FNTB | P49356 | 6/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412323 | 1.00 | APLNR (0.42) | APLNRCALCRGRPRFNTAFNTB | |
| SCHEMBL415551 | 0.97 | APLNR (0.42) | APLNRCALCRFNTAFNTBPGGT1B | |
| SCHEMBL415550 | 0.97 | APLNR (0.42) | APLNRCALCRFNTAFNTBPGGT1B | |
| SCHEMBL414401 | 0.95 | APLNR (0.41) | APLNRCALCRFNTAFNTBPGGT1B | |
| SCHEMBL414400 | 0.95 | APLNR (0.41) | APLNRCALCRFNTAFNTBPGGT1B | |
| SCHEMBL416410 | 0.90 | OPRM1 (0.39) | APLNR | |
| SCHEMBL416409 | 0.90 | OPRM1 (0.39) | APLNR | |
| SCHEMBL31256943 | 0.84 | OPRM1 (0.42) | — | |
| SCHEMBL29616320 | 0.83 | FNTA (0.45) | FNTAFNTBPGGT1B | |
| SCHEMBL29941145 | 0.82 | CCKAR (0.42) | CALCRKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220088042-A1 | COMBINATION THERAPY INCLUDING SAPC-DOPS FOR THE TREATMENT OF PANCREATIC CANCER | UNIVERSITY OF CINCINNATI | 2022-03-24 | — | — | US | disclosed |
| US-20120020878-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088042-A1 | COMBINATION THERAPY INCLUDING SAPC-DOPS FOR THE TREATMENT OF PANCREATIC CANCER | PNLIP, PLA2G2C, SMPD1 | APLNR 603/4885CALCR 3463/4885GRPR 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.